Xarelto Tablet, Film Coated
Product Images NDC 50090-3625

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Xarelto (NDC 50090-3625). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500903625)

The text appears to be a product description for XARELTO, including a product number (6831-0), tablet quantity (90), and possibly a price ($3625.0). It is unclear what "LoF" and "{Eavgononn Ay" refer to.*

FDA Label Image

Figure 1 (Xarelto 01)

This appears to be a table displaying different variables including hazard ratio, confidence interval, weight, age, prior stroke, diabetic status, and other variables. The table compares the likelihood of favoring Rivoxaban versus Warfarin in different populations.*

FDA Label Image

Figure 2 (Xarelto 02)

This appears to be a table with various medical variables and their corresponding values. The first column indicates the different variables considered, such as age, sex, weight, and medical history. The remaining columns show the percentage or number of cases in each category, but it is not clear what the context or purpose of the table is without further information.*

FDA Label Image

Chemical Structure (Xarelto 03)

FDA Label Image

Figure 3 (Xarelto 04)

The text describes the population description, fold change, and 90% CI of various groups including those with end-stage renal disease, renal impairment, age differences, bodyweight differences, and hepatic impairment. The post-dialysis and normal measurements were taken for patients with end-stage renal disease, and the findings here are from a single dose of rivaroxaban post hemodialysis. The text also includes the creatinine clearance values for the different levels of renal impairment. The findings are presented in terms of AUC, Cmax, and relative change to reference.*

FDA Label Image

Figure 4 (Xarelto 05)

The provided text shows a table that presents the fold change values and the 90% CI range for drug interaction PK in several drugs including inhibitors, inducers, and other groups. The drugs mentioned are Ketoconazole, Ritonavir, Clarithromycin, Erythromycin, Fluconazole, Rifampicin, Aspirin, Atorvastatin, Clopidogrel, Digoxin, Enoxaparin, Meloxicam, Midazolam, Naproxen, Omeprazole, and Ranitidine. The table also indicates the change relative to Rivaroxaban alone with time intervals of 0.25, 0.5, 1, 2, and 4.*

FDA Label Image

Figure 5 (Xarelto 06)

This appears to be a table with information about cumulative event rates (%), HR (95% CI), and the number of subjects at risk for XARELTO and Warfarin. The table also shows how many days have passed since randomization. There may be additional information in the full document, but this text alone is not providing enough context to determine exactly what the table is describing.*

FDA Label Image

Figure 6 (Xarelto 07)

FDA Label Image

Figure 7 (Xarelto 08)

FDA Label Image

Figure 8 (Xarelto 09)

FDA Label Image

Figure 9 (Xarelto 10)

FDA Label Image

Figure 10 (Xarelto 11)

FDA Label Image

Figure 11 (Xarelto 12)

This appears to be a graph showing the cumulative probability of a comparison between XARELTO + Aspirin and Aspirin. The comparison shows the Hazard Ratio (95% Confidence Interval). The graph is plotted against time in days from Randomization, with the number of subjects at risk indicated.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.